Abstract | Disease risk and treatment response are determined, at the individual level, by a complex history of genetic and environmental interactions, including those with our endogenous microbiomes. Personalized health care requires a deep understanding of patient biology that can now be measured using a range of '-omics' technologies. Patient stratification involves the identification of genetic and/or phenotypic disease subclasses that require different therapeutic strategies. Stratified medicine approaches to disease diagnosis, prognosis and therapeutic response monitoring herald a new dimension in patient care. Here, we explore the potential value of metabolic profiling as applied to unmet clinical needs in gastroenterology and hepatology. We describe potential applications in a number of diseases, with emphasis on large-scale population studies as well as metabolic profiling on the individual level, using spectrometric and imaging technologies that will leverage the discovery of mechanistic information and deliver novel health care solutions to improve clinical pathway management.
Introduction
Any predictions about the disease risk of an individual or a population require an understanding of the complex gene-environment interactions that affect our physiology and health. Systems medicine embodies the conceptualization of these interactions in the patient and is, by definition, a holistic approach to diagnostics and prognostics based on the in-depth knowledge of patient biology.
The notion that most medical specialties are administered in discrete silos, with patients attending separate clinics for each condition, still persists in mainstream medicine. The move towards personal or stratified medicine calls for a patient-centric approach, in which a global view of health demands knowledge of the integrated output of multiple systems and organs. 1 The realization that has propelled the advance of systems biology and systems medicine is that, if we are to truly understand disease mechanisms, we need to adopt a global investigative approach combining multiple bioorganizational layers, such as the genome, proteome, metabolome and inflammasome. Parallel development of '-omics' tools and advanced bioinformatics can be harnessed to help achieve this goal. In the past decade, attention has turned to the effect of the gut microbiome and its interaction across multiple bio-organizational levels in its human host, influencing the epigenome, m etabolome and inflammasome. 2 Depersonalized or 'one-size-fits-all' treatments are the default approaches used for most patients, which can negatively affect the success of clinical trials, the costeffectiveness of therapies and, ultimately, patient safety. 3 Variations in genetic profile, differential gene expression and gene-environment interactions all influence an individual's risk of developing a particular disease and the subsequent response to medication. Genetic classifications of disease subtypes are well established, and modern genomic methods can provide rich information about large numbers of patients at fairly modest costs. However, there are orthogonal and highly complementary approaches to patient stratification based on proteomic and metabolic information that can help place underlying genetic information in a biochemical or physiological context. These approaches can also measure differential environmental, dietary and gut microbial contributions to patient diversity and response. Thus, even within selected disease subclasses that are defined by the same genetic abnormalities, observed variation in therapeutic response is dependent on environmental factors and conditional gene-environment interactions. In particular, metabolic and other clinical phenotyping approaches are of value in patient characterization and can be used to monitor direct responses to therapies throughout the patient's journey. 4, 5 The 21 st century heralds a move towards predictive, preventive, personalized and participatory (P4) approaches to medicine, 6 whereby each person serves as their own control over time. An individual's wellbeing is markedly influenced and modified by environmental exposures, with outcomes being determined by the individual's genetic background, but also an overall investment in their own health care. 7 In addition to the contribution of the human genome to disease risk, the role of the gut microbiota in personalized health care is now widely recognized. For example, the underpinning chemical signalling between microbe and host is a major new area for academic study as the microbiome affects metabolic p henotype variation. [8] [9] [10] The fundamental paradigm of clinical metabolic pheno typing is that any localized metabolic, physical or histological perturbation in the human body will result in global changes, which can be characterized by profiling thousands of system parameters in biological samples such as urine, serum or tissue (intact or extracted). Localized and systemic metabolic phenotypes in tissue compartments and biofluids are the products of geneenvironment interactions and are statistically and biologically connected to disease risk factors and individual responses to therapy. 5, 11 Alterations in metabolic profiles will therefore be characteristic of the origin, behaviour and outcome of the original disease manifestation. We, and others, have developed novel and innovative molecular diagnostic phenotyping approaches for patient stratification across a range of technology platforms with applications in many different pathological disease states and clinical conditions. [12] [13] [14] [15] Modelling responses to therapy via metabolic phenotyping can be viewed as a 'dynamic patient stratification' process, which adds a new temporal and physiological dimension to understanding therapeutic response classes. 4 In this Review, we describe applications of metabolic profiling in gastroenterology and hepatology and explore potential avenues for its application to address key unmet needs in these areas.
Metabolic phenotyping in the clinic
Metabolic profiling of biofluids using predominantly NMR spectroscopy and mass spectrometry enables a fairly high-throughput generation of molecular fingerprints at low cost per sample. These techniques have been used to characterize a wide range of pre-pathological and pathological conditions including cardiovascular disease, 16 cancer, neurodegeneration, 17 metabolic disorders [18] [19] [20] and infection. 21 Profiling can be carried out in screening mode, to obtain broad coverage of the metabolome without the need for a priori hypotheses, or in targeted mode, to give deep coverage for selected metabolite classes, for example amino acids, eicosanoids (inflammatory conditions), bile acids (liver disease) or short-chain fatty acids. An outline of the main metabolic profiling platforms with their relative strengths and limitations is provided (Table 1) along with a schematic showing the analysis flow (Figure 1 ).
Key points
■ Spectroscopically directed metabolic profiling has the potential to enhance current capabilities in patient stratification ■ Examples of the contribution of metabolic profiling to disease diagnostics and prognostics as applied to liver and digestive diseases are widely present in the literature ■ Metabolic profiling provides insights about the function of gut bacteria, which are known to be involved in a wide range of pathologies including IBD, obesity, fatty liver and colorectal cancer ■ Surgical metabonomics centred on mass-spectrometry-linked intelligent surgical devices have the potential to deliver clinically relevant chemical information in real-time to augment clinical decision-making NMR spectroscopy is rapid and nondestructive and has the advantage of high reproducibility; it is the only spectroscopic tool that can deliver atom-centred information, giving it premium position in molecular structural elucidation. 22 Mass spectrometry offers complementary molecular information and is inherently more sensitive than NMR, but intrinsically less robust. One of the first medical applications of both NMR and mass spectroscopic profiling in stratified medicine was the identification of infants with congenital metabolic dysfunction. This technology is now routinely used in hospitals to identify conditions such as phenylketonuria, maple syrup urine disease and renal Fanconi disease. 23, 24 Ultra performance liquid chromatography (UPLC), used as a molecular separation phase before mass spectrometry detection, provides rapid analysis and delivers excellent chromatographic resolution. 25 Concatenation of NMR systems with liquid chromatographic devices and mass spectrometers offers exquisite capability for enhanced structure elucidation 26 and is equally applicable to the identification of endo genous and drug metabolites, although the majority of publications using this technology have focused on drug metabolism. 27 Metabolic screening of biofluids has been at the forefront of profiling technologies in the clinical arena, but other spectroscopic tools have been developed for the assessment of tissue biopsy samples. Among these, magic angle spinning (MAS) NMR methods, operating on a 5-15 min per sample timescale, enable metabolic characterization of intact tissue samples, including differentiation between benign and malignant tissue and the assessment of tumour grade or stage. 28, 29 Related developments in molecular imaging of tissues to improve clinical d ecision-making and augment conventional histological and clinical pathology measurements are also being undertaken in cancer diagnostics 30 and are ready for further development in an experimental medicine environ ment. Current histopathological techniques offer little interpretable molecular information, without the use of specific nonroutine stains or immunohistochemical procedures. Advances in desorption electrospray ionization (DESI) 31 and matrix-assisted laser desorption ionization-imaging mass spectrometry (MALDI-IMS) technology 32, 33 enable multimodal tissue imaging using thousands of simultaneously collected molecular ion traces. These tools can be used to provide new spatially resolved molecular biomarker information relevant to disease aetiology and d iagnostics as well as new imaging modalities.
These enabling technologies are complemented by the development of innovative bioinformatic and modelling methods to enhance the understanding of the whole system including relationships between other '-omics' data. In parallel with spectroscopic developments, many computer-based preprocessing and multivariate modelling techniques have been created to facilitate the analysis and interpretation of complex high-density spectral data. Computational modelling tools are able to analyse, map and interpret spectroscopic data and can be roughly divided into different categories: preprocessing methods (such as spectral alignment and de noising [34] [35] [36] ); multivariate analysis methods (extensions to linear projection methods, Bayesian probabilistic models and so on [37] [38] [39] ); biomarker extraction algorithms (based on statistical spectroscopic tools 40 ) and pathway integration and mapping tools (such as Metabonetworks 41 and MetaMapp
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). Datafiltering strategies and other pre processing methods can be used to optimize models and to increase the interpretability of models focusing on important biochemical changes relating to single or combinatorial pathologies by removing extraneous variation. 43, 44 Data-fusion methods have also been developed to interrelate and interpret multiple data matrices, such as NMR, clinical chemistry or gene expression, to achieve a more holistic picture of the dynamic and interactive biological processes in the individual. [45] [46] [47] Statistical correlation methods applied to spectroscopic data can be used to find candidate biomarkers for a disease, to identify drugs and their metabolites 48, 49 and to establish pathway connections between molecules. Modifications of the basic statistical spectroscopy focus on the identification of metabolites in fairly small subsets, which are otherwise hidden in large patient numbers, or on the detection of idiosyncratic responses to drugs (for example, subset optimization by referencing matching, STORM). 50 All of these methods and approaches aid in the efficient extraction and validation of biomarker structure information, which provides the mechanistic underpinning of the diagnostic and prognostic information g enerated by spectroscopic phenotyping.
Infrastructure frameworks based on the new spectroscopic technology and statistical methods will have the capacity to bridge gaps between population phenotyping and real-time diagnostics, and to place the resulting information within a systems medicine framework. We illustrate a potential framework to match research imperatives and enable technologies to address the disconnect between stratified medicine and public health care research paradigms ( Figure 2) . Ultimately, the aim is to harness the power of '-omics' technologies for mainstream use in clinical decision-making and improve patient care. We demonstrate the potential of metabolic profiling in exemplar studies chosen to represent different analytical methodologies and biological matrices and highlight the clinical relevance and limitations of each study (Supplementary Table 1 ). Although the potential of the metabolic phenotyping strategy is obvious, the field is somewhat plagued by a lack of validation cohorts and the outcomes of most studies to date have been confounded by low sample numbers. A further shortcoming of many metabolic profiling studies is that the significance statistics reported for candidate biomarkers are not corrected for multiple testing using methods such as the Bonferroni correction, which is essential given the number of parallel tests conducted for a typical spectral dataset (which can be in the order of hundreds or even thousands).
Unmet clinical needs
Liver disease is a major cause of premature mortality, and rates are increasing in developed and developing countries alike with the combined burden of viral hepatitis, increased alcohol consumption among young people and the prevalence of obesity. Over the past three decades, in the UK alone, deaths from chronic liver disease have increased eightfold in men aged 35-44 years and sevenfold in women of the same age group. 51 Thus, one of the greatest unmet needs in medicine today is the ability to accurately identify and stratify early stages of liver disease. Hepatocellular carcinoma (HCC) is the most common primary liver cancer worldwide, killing up to one million people per year, most of whom have established cirrhosis as a precursor. 52 Many of these deaths are preventable. HCC can be managed if patients with pre-existing fibrotic and cirrhotic liver disease are regularly screened and the cancer is diagnosed early. However, small tumours are asymptomatic and standard diagnostic screening tests lack the sensitivity and specificity to detect them.
Similarly, the incidence of IBD, particularly Crohn's disease and ulcerative colitis, has increased markedly in the developed world in the past decade. 53 Much of this increase in prevalence has been attributed to lifestyle changes, such as increased consumption of fast food with a corresponding decrease in dietary fibre. An association between these unhealthy eating trends Nature Reviews | Gastroenterology & Hepatology b | The spectra generated contain many thousands of data-points and require computational preprocessing and modelling to identify meaningful chemical structure within the spectral data. c | Pathology-related signatures are extracted from the models and bioinformatics approaches applied to enhance molecular identification and to map discriminatory metabolites to biochemical networks with the aim of improving mechanistic knowledge of pathological processes. Abbreviations: CE-MS, capillary electrophoresis-mass spectrometry; DI-MS, direct injection-mass spectrometry; GC-MS, gas chromatography-mass spectrometry; LC-MS, liquid chromatography-mass spectrometry; REI-MS, rapid evaporative ionization-mass spectrometry.
and the prevalence of colonic cancer is also evident.
54
In both gastroenterology and hepatology, the immediate clinical needs in terms of novel diagnostics also require supporting mechanistic understanding to translate new knowledge into more, effective treatment strategies.
Applications of metabolic profiling
Many potential avenues have been suggested for the application of metabolic phenotyping, in particular with regards to current unmet diagnostic needs in gastroenterology and hepatology. The following section addresses some clinical scenarios in which metabolic phenotyping has shown promising results and draws examples from the perspective of diagnosis, prognosis and response monitoring.
Dysbiosis
The gut microbiota in disease The role of the gut is pivotal in many genetic and environmental interactions in an individual and hence intestinal health or the lack of it might closely map to a variety of noninfectious diseases that are not related to gut disorders per se. Microbiota and microbiome contribute to the risk and/or progression of several hepatological and gastroenterological diseases. Microorganisms inhabit many areas of the human body, including mouth, nose, skin, vagina and gut, with the vast majority residing in the gastrointestinal tract. 55 Over time, the host co-evolves with its microbial residents, and establishes a mutually beneficial host-microbiota relationship. Microbially derived metabolites can influence host biochemistry and affect the health status of the host. 56, 57 Biospecimens, such as urine and faeces, contain molecules originating from microbial metabolism, hence metabonomics is ideally placed to report on the functionality of gut microbial communities and to explore the influence of the gut microbiota on host metabolism. The microbiota is key to the status of the immune system, affects a diverse range of tissues and organs, including the liver and brain, and is implicated in the aetiology of many diseases including IBD, cardiovascular disease, asthma and even neurodevelopmental conditions such as autism. 58 Given the close relationship between the gut and liver (the 'gut-liver axis'), the intestinal microbiota has been widely recognized for playing a key part in the maintenance of intestinal and hepatic function. Examples of conditions associated with dysbiosis include small intestinal bacterial overgrowth (which has been correlated with the severity of cirrhotic liver disease 59 ), the interaction of alcohol with gut bacteria (increased serum lipopolysaccharide levels are associated with alcoholic pancreatitis 60 ) and the close association of the gut microbiota with the development of NAFLD. 61 Metabonomic studies comparing germ-free rat and mouse models with conventionally housed animals have demonstrated the effects of the microbiota on the metabolism of bile acids [62] [63] [64] [65] and the potential to influence host susceptibility to drug-induced liver toxicity. 66 Other examples of microbial-related differences in the phenotype include the finding that malignant gastrointestinal tumours carry differential 16S ribosomal RNA bacterial profiles. 67 Critical biosynthetic pathways that substantially extend host metabolic capacity are introduced by microbes, for example affecting the biosynthesis of a number of B vitamins. 68 Metagenomic analysis can be used to map the microbial community of faecal or intestinal samples. Parallel metabolic profiling of biofluids such as urine, plasma or faecal water can provide a window to investigate the functionality of the microbiota and assess consequences on human health. Altered microbial activity, which is evident in microbial-host co-metabolite profiles, can also be detected with these methods. A study in obese individuals with NAFLD presented evidence of a tripartite relationship between host metabolism, me tagenome and bacterial metabolism. 69 
Faecal microbiota transplantation
Faecal microbiota transplantation (FMT), also referred to as faecal bacteriotherapy, has therapeutic potential in persistent Clostridium difficile infections (CDI), with >90% cure rates in many instances. 70 FMT has also been used experimentally in patients with severe IBD. The procedure involves the removal of existing gut bacteria using antibiotics and their replacement with faecal matter from a healthy donor, whether in the form of an enema (a fluid injected into the lower bowel via the rectum) or delivered by nasogastric tube. This method might eventually be replaced by a procedure in which encapsulated bacteria from healthy faeces are transplanted. The first reported transplant was carried out in 1958 on a patient with CDI. 71 Since then, several studies in patients with recurrent CDI have reported success following a single infusion. A literature review that collected data on FMT in 317 patients with CDI showed that >90% of patients experienced a resolution of the disease. 72 A metabonomic study focusing on liquid chromatography followed by mass spectrometry (LC-MS) profiling of faecal bile acids in 12 patients 3 weeks after surgery provided evidence that cholic and cheno deoxycholic acids dominate the profile pre-transplantation, whereas the landscape changed to favour lithocholic acid, deoxycholic acid and isodeoxycholic acid post-transplantatio n. 73 The change in bile acids was accompanied by an increased diversity within the microbiota, decreased presence of Proteobacteria and increased numbers of bacteria from the Firmicutes and Bacteroidetes phyla after the transplant. Whereas firm Nature Reviews | Gastroenterology & Hepatology Data integration and informatics: data-to-knowledge Integrated metabolic databases, clinical and '-omics' data-fusion, pathway modelling and visualization, and clinical actionability medical consensus on the benefits of faecal bacteriotherapy in CDI has been achieved, the literature addressing the value of this procedure in IBD is less clear. Several studies have assessed the effects of FMT on resolution of gut-bacterially-influenced disease, such as CDI and IBD, and have generated conflicting results. 74 A meta-analys is of faecal transplants as therapeutic IBD intervention reviewed 18 separate studies from which they concluded that in 45% of patients clinical remission was achieved, with higher success rates for Crohn's disease (60.5%) than for ulcerative colitis (22%). 75 Faecal metabolic profiling of patients infected with C. difficile who underwent FMT showed a clear change in the bile acid metabolite profiles associated with recovery. 73 This therapy undoubtedly has the potential to aid in the treatment of gastrointestinal disorders, but more research into the mechanisms of remission, the effect of the donors' microbiota composition and procedure methodology is required.
IBD
The development of urine and serum biomarker diagnostic strategies in IBD, particularly for Crohn's disease and ulcerative colitis, has generated marked interest. Biomarkers could be a beneficial noninvasive adjunct to current methods of diagnosis. Distinguishing between Crohn's disease, ulcerative colitis and other inflammatory bowel conditions remains difficult. Diagnosis is based upon clinical symptoms, endoscopic examination, radiographic data and histological evidence and is therefore an invasive and costly process. 76 Specific biomarkers of IBD variants would be of immense clinical value. As the manifestation of Crohn's disease is heterogeneous and disease severity does not always mirror the endoscopic profile, new measures of disease presence and stage are needed. To this end, numerous proteomic 77 and genomic 78 studies have been conducted, but although >100 genetic loci have been associated with Crohn's disease, the genotype does not relate to subphenotypes of Crohn's disease and is not predictive of recurrence following treatment. [77] [78] [79] To date, only a few metabolic studies have been piloted on serum or plasma from patients with IBD. Dawiskiba et al. 80 conducted a NMR-based metabolic profiling study in patients with IBD (n = 19 Crohn's disease; n = 24 ulcerative colitis; n = 17 healthy individuals as controls) and did not find a clear separation between the metabolic profiles of patients with Crohn's disease and ulcerative colitis, although there was evidence of a specific 'fingerprint' associ ated with active IBD and IBD in remission. However, the demographics in this study were not entirely balanced, with a greater male:female ratio and a broader age range in the ulcerative colitis class. Elevated levels of N-acetylated glycoproteins (acute-phase reactive proteins) have been associated with inflammation; in this study, phenylalanine was found to be increased in the serum of patients with IBD, whereas their urine was character ized by higher glycine and lower acetoacetate levels, compared with healthy individuals. 80 Levels of additional metabolites were found to be increased (leucine, isoleucine, 3-D-hydroxybutyrate, acetoacetate, glycine and l-lactate) or decreased (creatine, histidine, choline) in the serum, when individuals with active disease were compared with healthy participants. 80 Similarly, urine profiles showed differentiation based on reduced excretion of hippurate, trigonelline, citrate and taurine, when active disease was compared with controls. 80 In contrast to the results of Dawiskiba et al., 80 Williams et al. 81 found that it was possible to differentiate Crohn's disease from ulcerative colitis in a similarly sized age-matched and gender-matched cohort (n = 24 Crohn's disease; n = 20 ulcerative colitis; n = 23 healthy individuals as controls), based on NMR serum profiles. The levels of N-acetylated glycoproteins, choline and lipoproteins were key discriminatory factors. 81 Fathi et al. 82 performed a random forest analysis (statistical classification method using binary decision trees to achieve optimal classification based on iterative training and testing of a dataset) of low-molecular-weight serum profiles to distinguish patients with Crohn's disease from healthy participants (n = 26 Crohn's disease, n = 26 healthy controls, age-matched and gender-matched). The resulting model predicted Crohn's disease with a sensitivity of 100% and a specificity of 88%, based on elevated isoleucine concentrations and decreased valine concentrations in participants with Crohn's disease. 82 The altered levels of these amino acids were attributed to the altered nutritional status often found in patients with Crohn's disease. The authors further assessed the profiles with respect to serum zinc levels, as low Cu 2+ /Zn 2+ superoxide dismutase activity has been associated with IBD. 82 A correlation between serum zinc levels and serum glutamine and lysine was established. One hypothesis arising from this study was that patients with Crohn's disease might be susceptible to glutamine depletion, given that glutamine is an essential nutrient for immune cells, which are highly overactive in IBD. 82 Associations between the intestinal microbiota and IBD have been documented. 83 When urinary metabolic profiles from healthy individuals and participants with ulcerative colitis and Crohn's disease were compared, specific urinary metabolites enabled the differentiation between disease cohorts. 83 Substantial differences were apparent in the levels of hippurate, 4-cresyl sulfate and formate. These metabolites are all connected with gut microbial activity. Most noteworthy was hippurate, which was found to be reduced in patients with Crohn's disease, compared with patients with ulcerative colitis and healthy participants. 84 However, low hippurate levels have also been associated with high BMI and blood pressure levels. 16, 85 Further studies will be necessary to clarify the relationship between faecal metabolic phenotypes, urinary metabolic phenotypes and gut microbial composition.
Colorectal cancer
Colorectal cancer (CRC) is the fourth most common cause of cancer-related mortality worldwide. 86 NMR and mass spectrometry have expanded the knowledge of tumour pathogenesis by enabling metabolical profiling of solid CRC tumours. 28, 87 Although tumour tissue generates informative profiles, tissue samples are by nature less suitable as a means to arrive at a diagnosis. Using a combined analytical strategy comprising NMR and gas chromatography-mass spectrometry (GC-MS), clear metabolic differences in tumour tissues obtained from colon and rectal locations can be identified, based on eicosanoid, lipid and steroid metabolism. 88 Other NMRbased studies have identified elevated lactate, threonine, serine, acetate, succinate, formate and tyrosine levels with lower concentrations of taurine, creatine, betaine and myoinositol in tumour tissue compared with adjacent nonmalignant tissue. 89 In terms of biofluids, studies using GC-MS, NMR, LC-MS, capillary electrophoresis-mass spectrometry (CE-MS) and MALDI-MS, all report consistent differences between biological samples from healthy individuals and patients with cancer. Numerous metabolic profiling studies have found differences in the serum of patients with CRC in comparison with healthy individuals and, in some incidences, patients with polyps. However, many of these studies have been compromised by low patient numbers and most do not have a comparison with other cancers, thereby neglecting to assign specific metabolic features to CRC. Differential metabolites in patients with CRC include lower serum levels of tricarboxylic acid cycle intermediates, 90 higher levels of glucose, pyruvate and lactate consistent with the Warburg effect, higher serum concentrations of 2-hydroxyglutarate, 2-hydroxybutyrate, kynurenine and sarcosine (also found to be increased in tumour tissue) compared with healthy individuals, 91 and differences in the concentrations of bile acids, amino acids, purine metabolism and gut-microbiota-derived metabolites. [92] [93] [94] Deconvolving systemic cancer-mediated effects such as cachexia from tumour-specific markers is a daunting task and, in reality, observed differences in ketone bodies and metabolites of muscle breakdown are more likely related to cachexia than the tumour itself. Clearly, more studies are required that compare metabolic signatures of multiple cancers to establish core and unique metabolic features for each of these conditions. A prospective CRC biomarker study found no association between serum metabolic profile and cancer risk although a positive correlation between serum glychochenodeoxycholate concentrations and CRC was found in women. 95 Urine studies indicate several volatile organic metabolites as candidate markers for CRC, easily detected by GC-MS 96 and alterations in gut microbial metabolites. Patients with adenomatous polyps, a precursor of CRC, can be identified with a sensitivity of 64% and specifi city of 65% using a machine learning algorithm to analyse 1 H-NMR spectroscopic profiles. 97 Studies associating the faecal metabolome with CRC have also been performed, but owing to the temporal and local variability in faecal composition, the number of participants required to generate meaningful conclusions is large. 98 Faecal samples from patients with CRC (n = 11) differed from healthy individuals (n = 10) in relative concentrations of fructose, linoleic acid, nicotinic acid. 99 A more reliable approach, both in terms of characterizing the metagenome and the metabolome, would be to directly analyse colonic contents.
Other studies have used model cell systems to evaluate potential therapeutic and preventative agents such as polyphenols and they have been able to show modulation of glutathione metabolism and polyamine levels. 93 Thus, strong validation studies extending across multiple cancers are required, although it is clear that metabolic profiling can identify distinct differences between patients with cancer and the healthy population. These studies will have to validate candidate biomarkers from the primary studies and drive hypothesis testing, taking into account the dysregulation of metabolic pathways indicated in these early studies.
Viral hepatitis
HCV infection is a global health problem, with 130-170 million people currently infected worldwide. 100, 101 The infection can lead to chronic liver inflammation, fibrosis, cirrhosis and, ultimately, HCC. 102 The clinical spectrum and natural history of chronic liver disease is varied with some individuals having a rapidly progressive course and others having fairly indolent disease. Wide geographical variability exists in disease prevalence. For example, in northern Europe, chronic infection rates are estimated to be between 0.1% and 1%. In southern Europe, rates are higher at 2.5-3.5%. 103 Egypt is worst affected with a prevalence of 22% or higher, owing to the transmission of HCV during the parenteral antischistosomal therapy campaign in the 1970s and 1980s. 104 In about 80% of new cases, the infection becomes chronic. About 30% of individuals progress inexorably to develop cirrhosis over a variable period of up to 20 years after the initial infection, which is usually 5-10 years after initial clinical presentation because of symptoms (HCV infection can be asymptomatic for 10 years). 102 Current treatment regimens are designed to prevent the progression from mild hepatitis to fibrosis and cirrhosis. 105 The late manifestation of HCV-related symptoms, and the expensive serological tests and analytical methods to identify HCV infection signify diagnostic conundrums, especially in developing countries. 106 To date, metabonomic studies of plasma from patients with hepatitis have largely concentrated on profiling the lipid content. 107 Distinct clusters of lipids correlate with markers of inflammation (IFN-α and IL-6), microbial translocation (lipopolysaccharide and lipopolysacharidebinding protein), and hepatic function (bilirubin). Lipid alterations in hepatitis showed substantial overlap with those reported in NAFLD. 108 Increased bile acids (glycocholate, taurocholate and taurodeoxycholate) were associated with noninvasive markers of hepatic fibrosis and correlated with acylcarnitine, a marker of mitochondrial dysfunction. 109 Urinary metabonomics has been shown to be useful in a study in which a panel of 11 discriminant metabolites was found using UPLC-MS. 110 Similarly, using urinary NMR profiling, investigators found that discriminant metabolites distinguish patients with hepatitis B from those with cirrhosis or liver cancer. 111 Liver cancer Liver cancer is the second most common cause of cancer mortality worldwide after lung cancer; in some parts of the world it is a leading cause of death in young people under the age of 40 years. 51 This alarming mortality is a result of an increase in risk factors for liver cancer, such as metabolic syndrome, hepatotropic viral infections, alcohol and exposure to toxins. 112 HCC is the most common type of primary liver cancer worldwide. Most HCCs develop from chronic liver disease, in particular cirrhosis. Whereas the highest prevalence is in Africa and Asia (where HBV and HCV are the most important risk factors), the additional problems of excess alcohol consumption among the young and a growing prevalence of obesity mean that, even in the developed world, HCC rates are rising steadily. 51 In many countries, the prognosis for patients with HCC is poor, with 5-year survival of <5%. If diagnosed early, HCC is curable by liver transplantation, surgical resection, radio frequency ablation or chemoembolization. 113 HCC survival is still low, even in Europe and North America, because patients often present late, when tumours are too large for curative treatment. Current gold standard screening tests for HCC diagnosis are 6-monthly ultrasono graphy scanning and blood analysis for α-fetoprotein (AFP) levels in patients with known liver disease. 114 However, these tests are expensive, only have 75-80% sensitivity and specificity and are not performed routinely in primary care in the UK. AFP analysis alone only detects around 70% of HCC cases. 115 A diagnostic urine test for HCC would be a paradigm shift in liver cancer screening, potentially providing a practical, cost-effective test that is easy to use in primary care. Clinically and economically, this approach would have a global impact, not only in the UK, but also in severely resource-limited settings, such as Sub-Saharan Africa. 116 A study published in 2014 detailed the discovery and validation of a panel of biomarkers for the diagnosis of HCC in West Africans. 111 This work demonstrates the importance of robust validation in biomarker discovery studies. For studies in HCC, a key imperative of metabolic phenotyping is the ability to differentiate between cancer and liver cirrhosis or fibrosis. 113 Distinctions between these stages often rely on subjective scoring systems, such as Metavir or modified Ishak scores that are derived from histological assessment. 116, 117 In addition, the indicated scoring methods require invasive intervention, can be subject to sampling errors and do not yield any mechanistic information. 118, 119 The second most common type of primary liver cancers are biliary tract cancers. These tumours arise from the intrahepatic or extrahepatic bile ducts (for example, cholangiocarcinoma) or the gallbladder. 120 In the developed world, gallbladder cancer is more common in patients with cholelithiasis (gallstones), whereas the most common predisposing factor for cholangiocarcinoma is known to be primary sclerosing cholangitis. However, it has been estimated that up to 80% of cholangiocarcinomas are sporadic. 121 In East Asia, incidence of biliary tract cancer correlates with liver fluke infestation, which is endemic to countries through which the Mekong River traverses on its route from the Yunnan Province in China to southern Vietnam. 122 Current diagnostic tools, such as serum tumour markers (for example, carbohydrate antigen 19-9 and carcinoembryonic antigen) have poor sensitivity and specificity, and tissue biopsy samples can yield negative findings as a result of the desmoplastic nature of the malignancy. 121 Typically, patients with biliary tract cancer seek medical treatment at a late cancer stage. Once the presence of a malignancy is confirmed, surgical intervention is the only curative treatment, although even with surgery, p ostoperative survival is poor. 123 Urinary metabonomics has shown encouraging results in identifying potential discriminant biomarkers in populations with hepatitis and distinguishing patients with mild liver disease from those with cirrhosis or cancer. 21, 124 If borne out in larger studies, these data might hold promise for the development of a urinary test, such as a dipstick, that could be used in rural populations to screen for early markers of primary liver cancer, reduce late presentation and improve outcomes.
NAFLD and NASH
Fatty liver, or hepatic steatosis, is a common finding in the general population and is a frequent cause for elevated serum aminotransferase levels. 125, 126 This condition is the hepatic manifestation of metabolic syndrome, which is characterized by insulin resistance and obesity, and has also been linked to diabetes mellitus and hypertriglyceridaemia. Steatosis can develop as a result of exposure to other risk factors, particularly alcohol abuse and HCV infection. NAFLD is defined as the presence of hepatic steatosis in individuals with minimal or no alcohol intake, encompassing a spectrum of diseases, ranging from simple steatosis to steatohepatitis (NASH), with or without the development of fibrosis and cirrhosis. Estimates of hepatic steatosis prevalence vary, but incidence rates are increasing all over the world and it is predicted that the direct and indirect global health care costs attributable to NAFLD will increase by 26% in the next 5 years. 127, 128 Hepatic steatosis is also the most common histological abnormality of the liver, affecting ~50% of patients who abuse alcohol. Similar to alcoholic liver disease, NAFLD can also progress to liver fibrosis, cirrhosis and cancer. 129 Metabolic profiling has been used extensively to further the understanding of the metabolic mechanisms involved in NAFLD. Human and animal models have produced putative biomarkers of liver dysfunction (reduced creatine levels) and inflammation (increased arachidonic acid levels) in NAFLD. 130 In other metabonomic studies, evidence was provided for the dysregulation of bile acid and phospholipid homeostasis with a concomitant upregulation of fatty acid β-oxidation. 107 In a large-scale metabolic profiling study conducted using UPLC-MS, a BMI-stratified statistical approach was used to separate patients with and without NASH, revealing a BMI-dependent serum metabolic profile. 131 Thus, metabonomic studies have the potential to provide insight into hepatic metabolism in health and disease, and aid targeted drug discovery, particularly when considered as a tool to characterize the obesogenic environment and interpret relevant gene-environment interactions.
Population and individual phenotyping
The enhancement of individual patient monitoring and treatment as they undergo a series of unique investigative and therapeutic procedures within the health care system will depend on a combination of scientific, social and economic factors. Biologically similar subpopulations of patients probably share similar postinterventional response REVIEWS trajectories that can be monitored in a dynamic environment. Combining the potential of advanced metabolic profiling technology with enhanced data processing capacity will enable a step-change in translational capability to meet the growing demand for dynamic patient stratification and improve delivery and sustainability of optimised health care. One could envisage, in an ideal world, a model that permits the sampling of patients during the entire journey from primary diagnosis to intervention and response.
The use of spectroscopic techniques to extract deep phenotypic descriptors and to follow the progression of these features through time is unprecedented in the clinical environment and is a powerful approach to dynamic patient stratification based on enhanced diagnostics. The advance of new methods, such as pharmacometabonomics, 132 high-fidelity mass spectrometry imaging techniques and sophisticated statistical tools for spectral and chemical image analysis facilitate enhanced biomarker recovery and identification of mechanistic pathways. The following paragraphs will give insights into different spectroscopic methodologies that can be used for patient or population stratification.
Metabolome-wide association studies
For population studies of chronic conditions (for example, cardiovascular or neurodegenerative diseases and metabolic syndrome), metabolome-wide association studies (MWAS) are a valuable method to identify associations between metabolic patterns and disease risk and/or prevalence, based on spectral data. 16, 133 MWAS harness the power of large cohorts of individuals to drive the elucidation of more subtle metabolic signatures associated with a disease. Similar to genome-wide association studies, MWAS data are being used to generate testable hypotheses that can enhance the mechanistic understanding of a pathology. 85, 134 For example, the potential role of the gut microbiota in the regulation of serum trimethylamine-N-oxide levels and its negative effect on cardiovascular disease. 133 The MWAS approach has yet to be adopted in gastroenterology and hepatology, although analytical and computational advances have made highthroughput screening more practical and large-scale studies, particularly in the area of cancer research, are beginning to appear. 54 Given the rising incidence of liver cancers, MWAS represent a promising strategy to identify e nvironmental factors associated with disease risk.
Pharmacometabonomics
Static patient stratification is based on predictive mathematical models derived from single measurements (a genetic or metabolic snapshot of a single blood or urine sample), whereas dynamic stratification enables the classification of patient responses by monitoring the continuous effect of therapy. Pharmacogenomics, or the study of the effect of genomic variation on treatment response, has been used as a framework on which to base patient stratification. For example, trastuzumab (a monoclonal antibody against the receptor tyrosine-protein kinase erbB-2 [HER2/neu] receptor) is effective as a chemotherapeutic agent in only 30% of patients with breast cancer, corresponding to those who overexpress the ERBB2 gene that encodes the HER2 protein. 135 The pharmacogenomic approach to patient selection can be complemented by pharmacometabonomics (the prediction of an individual's response to a drug, based on a baseline profile), which can capture the influence of both genetic and environmental contributions. 136 Pharmacometabonomics has been shown to be a useful tool in predicting adverse drug reactions, anti-cancer drug efficacy, drug pharmacokinetics and the liver toxicity responder or nonresponder status. 137, 138 We, and others, have applied pharmacometabonomics in dynamic personalized medicine studies, for example to identify patients with CRC who have a high susceptibility to capecitabine toxicity (an inhibitor of DNA synthesis, commonly used in CRC treatment), based on NMR spectroscopic models of blood plasma composition taken before intervention. 139 Pharmacometabonomics has the potential to impact beneficially on current health care guidelines and practices by identifying more effective means of patient management for both acute and chronic conditions as well as rare diseases. 140 Surgical metabonomics A major breakthrough in in vivo metabolic profiling has been achieved using thermal cell disintegration followed by mass spectrometry analysis of ionized metabolic constituents with the aid of rapid evaporative ionization mass spectrometry (REI-MS) technology. 141, 142 This technique has been applied to human tissues, cell cultures, bacteria and protozoa. 143 Thermal tissue disintegration is widely used in interventional medicine during surgical diathermy or ablation and the combination of these medical technologies with online mass spectrometry detection results in in situ and in vivo real-time metabolic profiling of vital tissues or associated microorganisms. REI-MS technology has been integrated in surgical handpieces, such as knives or lasers used during operations (commonly referred to as intelligent surgical devices). 144 This technology combines standard surgical dissection techniques with mass spectrometric analysis of the by-products (smoke, liquefied tissue) of the dissection. The smoke is directed into a mass spectrometer via a vacuum extraction device contained within the surgical handpiece and the resulting molecular fingerprint generated by the mass spectrometer is matched with a database containing signatures of healthy and patho logical samples. The main advantage is the instantaneous analysis of biopsy samples, which enables quick decision-making based on more detailed information than clinical scoring criteria or surgeon's intuition. REI-MS technology improves the outcomes in terms of patient stratification and subsequent treatment. The technology can also be used for point-of-care characterization of needle biopsy samples and the identification of mucosa-associated bacterial strains. 142, 143 In addition, REI-MS technology has the potential to transform many in situ analytical procedures, such as endoscopy.
Oncological surgery has remained largely unchanged for decades and clearance of tumour tissue is typically based on arbitrary and nonobjective measurements of clearance, which are often inadequate and with potentially serious consequences for the patient. For example, 30% of breast cancers require re-excision for positive margins. 145 Both NMR and mass spectrometry technologies have been used to improve surgical diagnosis. MAS NMR technology is able to determine robustly the difference between benign and malignant tissue in breast and colorectal samples with a high degree of sensitivity and specificity. 25 Mass spectrometric imaging (MSI) of tissues in situ creates a new layer of detailed molecular information that can be superimposed onto traditional histopathological images and opens up exciting new avenues in molecular pathology. The MSI segment uses the DESI method for imaging, which is particularly well-suited for spatially resolved meta bolic profiling of tissues. DESI was originally invented by Takats et al. 31 who further developed the approach in 2014, by improving spatial resolution, sensitivity and information recovery from frozen section material. 30 The method, as published in 2015, permits 10-500 μm deep imaging of frozen histological sections in variable resolutions. 146 The MSI metabolic profile can be interrogated by realtime multivariate statistical analysis of the data to achieve histopathological classification. Moreover, the specificity of the spectral profiles exceeds the level of standard, m orphology-based classification, enhancing diagnostic capability and providing more refined guidelines for tumour resection. MSI is capable of detecting changes not visible in histological segmentation (that is, metabolic changes in the tumour environment), which gives a new dimensionality to tissue analysis. The potential for MSI technology in clinical settings has been demonstrated, particularly owing to the development of an automated bioinformatics workflow to augment histopathology as well as untargeted and targeted biomarker discovery. 30 
Future developments
Interestingly, independent studies of the same disease in different patient groups do not always reveal the exact same biomarker patterns. This difference does not necessarily mean that the studies are incorrect or inconsistent, rather that the studies are incomplete for analytical or biological reasons. Multiple analytical technologies can be applied to study metabolic phenotypes and all have different analytical properties and capabilities. Any two independent analytical technologies can never cover the same range of metabolites with the same precision or sensitiv ity. NMR spectroscopic measurements are based on fundamental quantum mechanics, making them more analytically robust and reproducible than mass spectrometry, which, unlike NMR, can be directly affected by the physical and chemical composition of a sample and is prone to phenomena such as ion suppression, which makes absolute quantification more challenging. Nonetheless, mass spectrometry is generally more sensitive than NMR. Therefore, data obtained when using these approaches on the same samples are not identical but highly complementary. Even within mass spectrometry, multiple platforms are available with diverse measurement options (time of flight, triple quadrupole, ion trap, ion cyclotron resonance and more), which also have different detection capabilities. Biomarker recovery from each technology will be slightly different, even within identical samples, but, collectively, all techniques provide broad biomarker coverage for the disease in question. However, we and others have recognized the need for standardization and harmonization of metabolic pheno typing and biomarker modelling procedures for future clinical deployments of these technologies. 4, 147, 148 It is the mission of the Medical Research Council-National Institute for Health Research (MRC-NIHR) National Phenome Centre 149 to create standardized robust protocols for clinical and epidemiological phenotyping, 150 ,151 using a range of NMR and mass spectrometry methodologies. These protocols will enable future clinical harmonization on the level required for regulatory purposes, whereas publically available databases, such as the human metabolome database, 152 offer a useful starting point for metabolite identification. However, it is not sufficient to use databases alone for structural assignment. They must always be backed up with appropriate experimental validation data.
Another reason for different biomarker patterns within the same individual are sample differences. Biomarkers detected in the urine of a patient might or might not be the same as those observed in plasma because each fluid represents a different biological window on the disease. In addition to the facile analytical basis of biomarker recovery variation between different studies, different population cohorts show intrinsic biological variation in disease presentation resulting from variations in the genome, lifestyle and diet. Therefore, the exact chemical expression of a disease in the form of metabolic biomarkers will be a product of gene-environment interactions in the particular population of interest. Although this metabolic variation seems to complicate the identification of disease-specific biomarkers or diagnostic models, it is in fact consistent with current ideas on stratified medicine that recognize variations in disease genotypes and/or pheno types and the effect of variable disease phenotypes on response to disease and therapeutic interventions. 4, 153 In the future, the consolidated information gathered from different approaches will be needed to develop new personalized health care strategies that underpin precision medicine paradigms. 23 Metabolic phenotyping combined with molecular pathology demonstrates the potential to enrich stratified medicine research, through the development and integration of novel analytical technology hubs. This improvement will involve the development of high-throughput technologies for population phenotyping, clinical-imagebased diagnostics and journey modelling, each with the potential to substantially affect health care, building on and extending existing national facilities such as the MRC-NIHR National Phenome Centre 149 or the USA National Institutes of Health (NIH) metabolomics cores. 154, 155 The successful deployment of these technologies into the clinic requires harmonization of analytical approaches including experimental design, multivariate statistics and databases. 156 We foresee the creation of technology networks that will enable extensive data sharing. The validation of novel methods (Box 1) and their evaluation compared with current clinical gold standards is required to ensure performance is at least equal to or even exceeds current diagnostic and monitoring capabilities.
Globally, the new analytical platforms and bioinformatics approaches described in this Review will open new avenues in clinical research and have the potential to directly affect patient care (Figure 3) . The opportunity to create a paradigm shift in clinical capability leading to changes in practice could be made possible by a combination of factors. Synergy between clinicians and physical scientists and the availability of large, well-defined ethically approved patient study groups must be achieved, and novel and innovative analytical technology and statistical information recovery tools should be developed. Emphasis should be placed on the ability to capitalize on the analytical framework and data processing pipelines already established. Finally, the development of enhanced computational power is needed, and academics and clinicians need to be willing to engage with technology providers to develop new solutions and optimize phenotyping p latforms and methods.
Many of the current metabolic phenotyping approaches to stratified medicine worldwide are subjective, empirical, labour-intensive, unreliable and usually housed in disparate uncoordinated centres. A key goal will be the standardization of reliable, robust protocols and applications that show statistically superior performance to existing pathological and clinical methods. These applications should then be diffused internationally to efficiently and freely share the data, thereby increasing the statistical power of biomarker discovery studies.
In terms of clinical adoption of the new technologies, we would like to emphasize that new discoveries in the medical field have to overcome barriers of conservative attitudes that prevent them from being assessed regarding their efficiency and cost-effectiveness. For this reason, new methods in metabolic profiling need major investment to broaden their application base, and to develop a user community who will collaborate to validate applicability and robustness of the new methods in a range of clinical areas. In addition, by the nature of the novelty of these approaches, as yet undetermined applications will emerge from the user community to demonstrate how basic science can be applied to many areas of patient stratification, including therapeutic response, diagnostics, prognostics and improved mechanistic understanding of disease aetiologies. It is difficult, at this early stage, to determine where the biggest impacts will be.
Conclusions
Hepatic and gastrointestinal diseases are among the most complex conditions to diagnose and treat. They are both heavily influenced by environmental factors, such as diet and the gut microbiota. In addition, the early stages of development of many liver diseases are typically silent. Metabonomics is ideally suited as a platform to investigate the effects of diet and other environmental factors, such as gut microbial composition, on disease risk and outcome. Metabolic profiling can be a useful adjunct to clinical scoring systems for diagnosis of hepatic and gastric conditions and has shown promise in several published studies. However, the majority of early clinical studies published thus far have had limited value due to small sample sizes, poorly defined control groups and, above all, a lack of validation cohorts. As with many '-omics' studies, a tendency to publish lists of candidate biomarkers is evident, without follow-up in independent populations or testing of the biochemical pathways proposed in the original studies. Mechanistic studies in animal models, such as evaluating the effect of the gut microbiota on obesity-prone rats, have been developed with more rigour and have contributed to our global understanding of the tripartite relationship between diet, the microbiota and host metabolism in liver disease. The maturation of spectroscopic profiling technologies and the advent of some newer tools, such as intelligent surgical devices, to allow near real-time identification of tissue composition have developed hand-inhand with bioinformatics tools. Together, these advances lead us towards a holistic 21 st century approach to systems medicine. The main challenge for the research and clinical communities now is to join forces to test the value of these analytical tools in the clinic and to develop the appropriate databases and relevant training to allow these tools to become generically applicable. 
